ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Current Report on Form 8-K dated October 7, 2021. The filing reports corporate communications regarding clinical and preclinical drug-development updates; it does not present a quarterly or annual financial reporting period.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, cash-balance, or other financial metrics. The referenced press release is incorporated as Exhibit 99.1, but its substantive data is not included in the provided filing text.
Material Changes Versus the Prior Comparable Period
No financial or operating comparison with a prior period is provided. The reported developments are:
- Initial clinical data from an ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, combined with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide.
- Preclinical data for ORIC-114, a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2, including activity against exon 20 insertion mutations.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, forecasts, detailed management commentary, risk updates, contingencies, or unusual financial items. The clinical and preclinical results are drug-development updates and remain subject to the risks inherent in clinical trials, regulatory review, product development, and commercialization.
Investor Verification Checklist
- Review Exhibit 99.1 for the detailed ORIC-101 clinical data, including patient numbers, response measures, safety findings, and study limitations.
- Review Exhibit 99.1 for the ORIC-114 preclinical results, experimental models, efficacy measures, and safety or tolerability information.
- Verify subsequent clinical-development plans, trial milestones, regulatory interactions, and financing needs in later SEC filings.
- Confirm the company’s cash position, operating losses, cash runway, and other liquidity measures in the company’s latest periodic report, as these are not provided here.